Lancet 394:131138 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Your GP will start treatment at a low dose and gradually increase it whilst monitoring for side effects such as dizziness or sedation
Here's what we'll cover Here's what we'll cover Here's what we'll cover If you have type 2 diabetes, your body still makes insulin but either doesnt produce enough or cant use it effectively
Individuals experiencing symptoms such as fatigue, weakness, memory problems, or those with dietary restrictions (e.g., vegetarians and vegans) should consider B12 testing
GLUT4 is found in insulin-responsive tissues such as heart, adipose tissue, and skeletal muscle
The Tiered or Pay-as-You-Go Model In this structure, the price you pay is tied directly to the volume of medication you receive